Silenseed

Silenseed is a clinical stage biopharmaceutical company that develops proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’ novel drugs, used together with the new delivery system, the LODER™ (LOcal Drug EluteR), have the potential to be one of the most highly effective treatments for solid tumor cancers. Diseases that currently are included in the company’s pipeline are pancreatic cancer, prostate cancer and certain brain cancers.